The DOI matches its Crossref record; 338 of the 341 references it cites were found in a registry or an index.
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Open accessAbstract
Singal, Amit G.; Llovet, Josep M.; Yarchoan, Mark; Mehta, Neil; Heimbach, Julie K.; Dawson, Laura A.; Jou, Janice H.; Kulik, Laura M.; Agopian, Vatche G.; Marrero, Jorge A.; Mendiratta-Lala, Mishal; Brown, Daniel B.; Rilling, William S.; Goyal, Lipika; Wei, Alice C.; Taddei, Tamar H. Author Information
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Surgical resection is recognized worldwide as the preferred treatment for patients with early stage HCC, whereas liver transplantation is indicated in those with early stage disease who are not deemed suitable for resection7,22.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In general, European and US guidelines recommend more-restrictive criteria for resection than Asian guidelines7,22–27.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In particular, regimens including immune-checkpoint inhibitors (ICIs) are currently adopted as first-line therapies in clinical guidelines7.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Currently, clinical decisions are based on clinical factors including, but not limited to, performance status, tumour burden, liver function and comorbidities7.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Now the positive results of IMbrave 050 (ref. 12) have led to a revised management algorithm for patients with early stage HCC by incorporating adjuvant therapies in this disease setting7 (Fig. 4).”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 1×
“[309] mRECIST criteria has been proposed to adapt RECIST criteria to particularities of HCC, enabling capture of antitumoral response without observed shrinkage after local and systemic therapies.”
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationErdogan, D., Heijnen, B. H. M., Bennink, R. J., Kok, M., Dinant, S., Straatsburg, I. H., Gouma, D. J., & van Gulik, T. M. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00901.x · Cited by 11,656
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470 · cited 2×
“…PD-L1, plus bevacizumab, a monoclonal antibody targeting VEGF, as the preferred first-line treatment option for patients with advanced HCC. [312] The median OS of 19.2 months with atezolizumab plus bevacizumab is the longest median OS of any first-line treatment for advanced-stage HCC to…”
InfluentialMazzaferro, V., Regalia, E., Doci, R., Andreola, S. A., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,173 · cited 1×
“[206] 211] The main barrier to LT is a shortage of available liver allografts compared with demand, prompting an allocation system that directs access to deceased donor organs for patients both with and without HCC.”
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Self-citationCancer statistics for the year 2020: An overview
Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2021) · International Journal of Cancer · doi:10.1002/ijc.33588 · Cited by 6,308
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,974
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832 · cited 1×
“[320] In 2018, lenvatinib (an oral mTKI targeting vascular endothelial growth factor [VEGF]2 and other kinases) met its primary endpoint of noninferiority versus sorafenib in a global phase III randomized study, REFLECT.”
Research works printed but not linked: 2
- Marrero, 2021, GALAD score improves early detection of HCC prior to the diagnosis of HCC: A phase 3 biomarker validation study. Abstract #138, Hepatology, 74, 92A
- Dawson, 2022, ORAL SCIENTIFIC SESSIONS LBA 01: NRG/RTOG 1112: Randomized Phase III Study of Sorafenib vs. Stereotactic Body Radiation Therapy (SBRT) Followed by Sorafenib in Hepatocellular Carcinoma (HCC) (NCT01730937). Int J Radiation Oncol, Biol, Physics, 114, P1057
Cited by
Sorted by citations
Singal, A. G., Kanwal, F., & Llovet, J. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00825-3 · Cited by 1,029
Self-citationEASL Clinical Practice Guidelines on the management of hepatitis B virus infection
Cornberg, M., Sandmann, L., Jaroszewicz, J., Kennedy, P. T. F., Lampertico, P., Lemoine, M., Lens, S., Testoni, B., Wong, G. L., & Russo, F. P. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.03.018 · Cited by 480
Llovet, J. M., Kudo, M., Merle, P., Meyer, T., Qin, S., Ikeda, M., Xu, R., Edeline, J., Ryoo, B.-Y., Ren, Z., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00469-2 · Cited by 469
Self-citationAdjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391
Self-citationSangro, B., Chan, S. L., Kelley, R. K., Lau, G., Kudo, M., Sukeepaisarnjaroen, W., Yarchoan, M., De Toni, E. N., Furuse, J., Kang, Y. K., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.02.005 · Cited by 365
Self-citationKudo, M., Ren, Z., Guo, Y., Han, G., Lin, H., Zheng, J., Ogasawara, S., Kim, J. H., Zhao, H., Li, C., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02575-3 · Cited by 342
Self-citationLiver diseases: epidemiology, causes, trends and predictions
Gan, C., Yuan, Y., Shen, H., Gao, J., Kong, X., Che, Z., Guo, Y., Wang, H., Dong, E., & Xiao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02072-z · Cited by 416
Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Hwang, S. Y., Danpanichkul, P., Agopian, V. G., Mehta, N., Parikh, N. D., Abou‐Alfa, G. K., Singal, A. G., & Yang, J. D. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0824 · Cited by 359
Self-citationLiver cancer in 2021: Global Burden of Disease study
Tan, E. Y., Danpanichkul, P., Yong, J. N., Yu, Z., Tan, D. J. H., Lim, W. H., Koh, B., Lim, R. Y. Z., Tham, E. K. J., Mitra, K., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.10.031 · Cited by 238
Self-citationBCLC strategy for prognosis prediction and treatment recommendations: The 2026 update
Reig, M., Sanduzzi‐Zamparelli, M., Forner, A., Rimola, J., Ferrer, J., Burrel, M., García‐Criado, Á., Díaz, A., Llarch, N., Iserte, G., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.10.020 · Cited by 253
Self-citationChan, S. L., Sun, H., Xu, Y., Zeng, H., El‐Serag, H. B., Lee, J. M., Schwartz, M., Finn, R. S., Seong, J., Wang, X. W., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01042-6 · Cited by 262
Self-citationVitale, A., Cabibbo, G., Iavarone, M. A., Viganò, L., Pinato, D. J., Ponziani, F. R., Lai, Q., Gardini, A. C., Celsa, C., Galati, G., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00186-9 · Cited by 209
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology
Huang, D. Q., Singal, A. G., Kanwal, F., Lampertico, P., Buti, M., Sirlin, C. B., Nguyen, M. H., & Loomba, R. S. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00818-8 · Cited by 201
“…recommends surveillance in people with chronic hepatitis B (men older than 40 years and women older than 50 years) who are from countries where chronic hepatitis B is endemic, and suggests that people from Africa living with chronic hepatitis B start surveillance from the age of 30 years 28,29 .”
BackgroundMethodSelf-citationGe, J., Sun, S., Owens, J., Galvez, V., Gologorskaya, O., Lai, J. C., Pletcher, M. J., & Lai, K. (2024) · Hepatology · doi:10.1097/hep.0000000000000834 · Cited by 199
“[29,30] LiVersa gave the wrong justification for HCC surveillance in this case simply because the 2018 version was not available to it and “ restrictions ” placed by curated RAG data set.”
Rimassa, L., Chan, S. L., Sangro, B., Lau, G. K. K., Kudo, M., Reig, M., Breder, V. V., Ryu, M., Ostapenko, Y., Sukeepaisarnjaroen, W., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.03.033 · Cited by 190
Eslam, M., Fan, J., Yu, M., Wong, V. W., Cua, I. H., Liu, C., Tanwandee, T., Gani, R. A., Seto, W., Alam, S., et al. (2025) · Hepatology International · doi:10.1007/s12072-024-10774-3 · Cited by 200
“Based on cost-effectiveness analyses, when the incidence of HCC is > 1 or 2%/year, it is cost-effective to perform HCC screening/surveillance [295–297].”
InfluentialChanging etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide
Kim, D. Y. (2024) · Journal of Liver Cancer · doi:10.17998/jlc.2024.03.13 · Cited by 185
“71 On the other hand, the European Association for the Study of the Liver (EASL) highlights the importance of categorizing those who should be screened for HCC, thus EASL guidelines state that patients with noncirrhotic stage 3 fibrosis should be included in the surveillance program, although the…”
BackgroundBreakthroughs in Hepatocellular Carcinoma Therapies
Singal, A. G., Kudo, M., & Bruix, J. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.01.039 · Cited by 167
Self-citationCappuyns, S., Corbett, V., Yarchoan, M., Finn, R. S., & Llovet, J. M. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2023.2677 · Cited by 167
Self-citationFerraioli, G., Barr, R. G., Berzigotti, A., Sporea, I., Wong, V. W., Reiberger, T., Karlas, T., Thiele, M. S., Cardoso, A. C., Ayonrinde, O. T., et al. (2024) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2024.03.013 · Cited by 160
“Current guidelines recommend HCC surveillance in patients with cirrhosis and patients with chronic hepatitis B and high-risk features [116,117].”
BackgroundEASL Clinical Practice Guidelines on the management of autoimmune hepatitis
Dalekos, G., Gatselis, N., Drenth, J. P. H., Heneghan, M., Jørgensen, M., Lohse, A. W., Londoño, M., Muratori, L., Papp, M., Samyn, M., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.03.017 · Cited by 175
Wang, K., Xiang, Y.-J., Yu, H.-M., Cheng, Y.-Q., Liu, Z.-H., Qin, Y.-Y., Shi, J., Guo, W.-X., Lu, C.-D., Zheng, Y.-X., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02786-7 · Cited by 142
ACG Clinical Guideline: Focal Liver Lesions
Frenette, C. T., Mendiratta‐Lala, M., Salgia, R. J., Wong, R. J., Sauer, B. G., & Pillai, A. A. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002857 · Cited by 134
“These patients should undergo follow-up imaging as recommended for FLL in the AASLD Hepatocellular Carcinoma Guidance (145).”
MethodSelf-citationKinsey, E. N., & Lee, H. M. (2024) · Cancers · doi:10.3390/cancers16030666 · Cited by 145
“The American Association for the Study of Liver Diseases (AASLD) Practice Guidance recommends that all patients with cirrhosis of any etiology and non-cirrhotic chronic HBV undergo surveillance every 6 months [17].”
BackgroundInfluentialMASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges
Phoolchund, A. G. S., & Khakoo, S. I. (2024) · Cancers · doi:10.3390/cancers16020259 · Cited by 137
“While there are multiple proposed alternative staging systems, the Barcelona Liver Clinic Cancer (BCLC) (shown in Figure 2) is the most commonly used and is recommended by the AASLD [109] and EASL [77] to help guide treatment.”
MethodImmune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy
Seyhan, D., Allaire, M., Fu, Y., Conti, F., Wang, X. W., Gao, B., & Lafdil, F. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01308-4 · Cited by 138
Zavareh, M. S. R., Yeo, Y. H., Wang, T., Guo, Z., Tabrizian, P., Ward, S. C., Barakat, F., Hassanein, T., Dave, S., Ajmera, V. H., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.042 · Cited by 118
Self-citationEASL Clinical Practice Guidelines on TIPS
Bureau, C., Larrue, H., Cerisuelo, M. C., Miraglia, R., Procopeț, B., Rudler, M., Trebicka, J., VanWagner, L. B., & Hernández–Gea, V. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.01.029 · Cited by 104
AASLD IDSA Practice Guideline on treatment of chronic hepatitis B
Ghany, M. G., Pan, C. Q., Lok, A. S.-F., Feld, J. J., Lim, J. K., Wang, S. H., Kim, A. Y., Tang, A. S., Nguyen, M. H., Naggie, S., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001549 · Cited by 126
Singal, A. G., Sanduzzi‐Zamparelli, M., Nahon, P., Ronot, M., Hoshida, Y., Rich, N. E., Reig, M., Vilgrain, V., Marrero, J. A., Llovet, J. M., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.02.022 · Cited by 97
Self-citationSellers, Z. M., Assis, D. N., Paranjape, S. M., Sathe, M., Bodewes, F. A. J. A., Bowen, M., Cipolli, M., Debray, D., Green, N., Hughan, K. S., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000646 · Cited by 100
“[88,89] AFP is considered a biomarker for HCC and has been used in multiple liver diseases to detect HCC once the presence of cirrhosis has been established.”
BackgroundA Phase 3 Biomarker Validation of GALAD for the Detection of Hepatocellular Carcinoma in Cirrhosis
Marsh, T. L., Parikh, N. D., Roberts, L. R., Schwartz, M., Nguyen, M. H., Befeler, A. S., Page-Lester, S., Tayob, N., Srivastava, S., Rinaudo, J. A., et al. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.09.008 · Cited by 92
Self-citationMultiparametric MRI for characterization of the tumour microenvironment
Hoffmann, E., Masthoff, M., Kunz, W. G., Seidensticker, M., Bobe, S., Gerwing, M., Berdel, W. E., Schliemann, C., Faber, C., & Wildgruber, M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00891-1 · Cited by 103
“As a result, early stage HCC and HGDN show hypoenhance-ment in the hepatobiliary contrast phase.”
InfluentialHepatocellular carcinoma: Epidemiology, diagnosis and treatment
Mauro, E., de Castro, T., Zeitlhoefler, M., Sung, M. W., Villanueva, A., Mazzaferro, V., & Llovet, J. M. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101571 · Cited by 104
“19,20 In clinical practice, direct HVPG measurement is not always available, so surrogate markers such as platelet counts ( > 100,000/ μ l), absence of splenomegaly, and no portosystemic collaterals, are often used.”
InfluentialSelf-citationLatest advances in hepatocellular carcinoma management and prevention through advanced technologies
Addissouky, T. A., Sayed, I. E. T. E., Ali, M. M. A., Wang, Y., Baz, A. E., Khalil, A. A., & Elarabany, N. (2024) · Egyptian Liver Journal · doi:10.1186/s43066-023-00306-3 · Cited by 89
Alpha-fetoprotein: Past, present, and future
Yeo, Y. H., Lee, Y., Tseng, H., Zhu, Y., You, S., Agopian, V. G., & Yang, J. D. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000422 · Cited by 87
“…As such, AFP is currently recommended for HCC surveillance with ultrasound by both the American Association for the Study of Liver Diseases (AASLD) [100] and the Asian Pacific Association for the Study of the Liver (APASL), [74] although the use of AFP is not endorsed by the European Association…”
BackgroundSelf-citationSun, Y., Li, T., Ding, L., Wang, J., Chen, C., Liu, T., Liu, Y., Li, Q., Wang, C., Huo, R., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000934 · Cited by 87
“[15] Progression-free survival (PFS) was defined as the interval between resection and intrahepatic recurrence or extrahepatic metastasis.”
D'Alessio, A., Stefanini, B., Blanter, J., Adegbite, B., Crowley, F., Yip, V., Slater, S., Fulgenzi, C. A. M., Celsa, C., Manfredi, G. F., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00457-1 · Cited by 90
Self-citationGenetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of the Art Update
Sookoian, S. C., Rotman, Y., & Valenti, L. V. C. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.05.052 · Cited by 88
Narasimman, M., Hernáez, R., Cerda, V., Lee, M., Sood, A., Yekkaluri, S., Khan, A., Quirk, L., Liu, Y., Kramer, J. R., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000528 · Cited by 83
Self-citationDigestive cancers: mechanisms, therapeutics and management
Zhan, T., Betge, J., Schulte, N., Dreikhausen, L., Hirth, M., Li, M., Weidner, P., Leipertz, A., Teufel, A., & Ebert, M. P. A. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02097-4 · Cited by 90
Suddle, A. R., Reeves, H. L., Hubner, R. A., Marshall, A., Rowe, I. A. C., TINIAKOS, D. G., Hübscher, S. G., Callaway, M. P., Sharma, D., See, T. C., et al. (2024) · Gut · doi:10.1136/gutjnl-2023-331695 · Cited by 80
“145 The BCLC classification is endorsed by the European Association for the Study of the Liver 88 and the American Association for the Study of Liver Diseases, 146 and is widely used in Europe and North America, but not in Asia.”
EASL position paper on clinical follow-up after HCV cure
Reiberger, T., Lens, S., Cabibbo, G., Nahon, P., Zignego, A. L., Deterding, K., Elsharkawy, A. M., & Forns, X. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.007 · Cited by 74
Hepatocellular Carcinoma: A Comprehensive Review
Amin, N. A., Anwar, J., Sulaiman, A. A., Naumova, N., & Anwar, N. (2025) · Diseases · doi:10.3390/diseases13070207 · Cited by 82
“However, the AASLD currently advises against using liquid biopsy for HCC diagnosis outside research settings, pending further validation in large-scale prospective studies [63].”
InfluentialThe current landscape of the antimicrobial peptide melittin and its therapeutic potential
Zhang, H.-Q., Sun, C., Xu, N., & Liu, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1326033 · Cited by 73
Taddei, T. H., Brown, D. B., Yarchoan, M. M., Mendiratta‐Lala, M., & Llovet, J. M. (2025) · Hepatology · doi:10.1097/hep.0000000000001269 · Cited by 82
Self-citationDopazo, C., Søreide, K., Rangelova, E. B., Mieog, S., Carrión-Álvarez, L., Díaz-Nieto, R., Primavesi, F., & Stättner, S. (2023) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2023.107313 · Cited by 70
Artificial intelligence in liver cancer — new tools for research and patient management
Caldéraro, J., Žigutytė, L., Truhn, D., Jaffe, A., & Kather, J. N. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00919-y · Cited by 73
“This change has not only challenged our diagnostic capabilities, as our prior validated radiographic systems are not applicable in this cohort, but has also challenged our screening and surveillance practices 93 .”
Multidisciplinary care for patients with HCC: a systematic review and meta-analysis
Dahan, K. S. E., Reczek, A., Daher, D., Rich, N. E., Yang, J. D., Hsiehchen, D., Zhu, H., Patel, M. S., Molano, M. D. P. B., Sanford, N. N., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000143 · Cited by 69
Self-citationComparison of non-contrast abbreviated MRI and ultrasound as surveillance modalities for HCC
Kim, D. H., Yoon, J. H., Choi, M. H., Lee, C. H., Kang, T. W., Kim, H. A., Ku, Y. M., Lee, J. M., Kim, S. H., Kim, K. A., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.03.048 · Cited by 68
Li, M., Bhoori, S., Mehta, N. J., & Mazzaferro, V. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.05.037 · Cited by 70
Self-citationHepatocellular carcinoma and lipid metabolism: Novel targets and therapeutic strategies
Cao, L.-Q., Xie, Y., Fleishman, J. S., Liu, X., & Chen, Z. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217061 · Cited by 76
Yilma, M., Xu, R. H., Saxena, V., Muzzin, M., Tucker, L.-Y. S., Lee, J. D., Mehta, N. J., & Mukhtar, N. A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.35066 · Cited by 66
Self-citationWang, Z., Fan, J., Zhou, S., Sun, Y., Liang, F., Ji, Y., Gu, F., Li, T., Peng, L., Peng, T., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01720-9 · Cited by 72
Lee, Y. B., Nam, J. Y., Cho, E. J., Lee, J., Yu, S. J., Kim, H., Paeng, J. C., Yoon, J., & Kim, Y. J. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0581 · Cited by 63
Kulkarni, A. V., Tevethia, H. V., Kumar, K., Premkumar, M., Muttaiah, M. D., Hiraoka, A., Hatanaka, T., Tada, T., Kumada, T., Kakizaki, S., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102179 · Cited by 61
Self-citationZhou, J., Sun, H., Wang, Z., Cong, W., Zeng, M., Zhou, W., Liu, L., Wen, T., Kuang, M., Zhang, B., et al. (2025) · Liver Cancer · doi:10.1159/000546574 · Cited by 78
Cabibbo, G., Celsa, C., Rimassa, L., Torres, F., Rimola, J., Kloeckner, R., Bruix, J., Cammà, C., & Reig, M. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.01.018 · Cited by 62
Akahoshi, K., Shindoh, J., Tanabe, M., Ariizumi, S., Eguchi, S., Okamura, Y., Kaibori, M., Kubo, S., Shimada, M., Taketomi, A., et al. (2024) · Liver Cancer · doi:10.1159/000538627 · Cited by 59
Chen, K., Shuen, T. W. H., & Chow, P. K. H. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02684-w · Cited by 61
“…the highly heterogeneous nature of HCC. Firstly, non-invasive diagnosis of HCC be established in at-risk patients based on the characteristic “ arterial enhancement and delayed washout ” imaging feature without histological con fi rmation, with a sensitivity of 89% and speci fi city of 95% [83, 84].”
BackgroundLemaitre, L., Adeniji, N., Suresh, A., Reguram, R., Zhang, J., Park, J., Reddy, A., Trevino, A. E., Mayer, A. T., Deutzmann, A., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00828-8 · Cited by 64
Wang, M.-D., Xu, X., Wang, K.-C., Diao, Y., Xu, J., Gu, L., Yao, L., Li, C., Lv, G., & Yang, T. (2024) · Cancer Science · doi:10.1111/cas.16194 · Cited by 60
“3,4 For those with advanced-stage HCC who are not candidates for resection, the 5-year survival rate is fewer than 20%, indicating an extremely poor overall prognosis.”
BackgroundNeoadjuvant and adjuvant systemic therapy in HCC: Current status and the future
Singal, A. G., Yarchoan, M. M., Yopp, A. C., Sapisochín, G., Pinato, D. J., & Pillai, A. A. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000430 · Cited by 55
“[3,16,17] Surgical resection in early-stage HCC affords 5-year OS rates approaching 70% [18,19] ; however, recurrence occurs in 50% – 70% of patients at 5 years (Table 1).”
BackgroundResultInfluentialSelf-citationFinancial Burden of Hepatocellular Carcinoma Screening in Patients With Cirrhosis
Narasimman, M., Hernáez, R., Cerda, V., Lee, M., Yekkaluri, S., Khan, A., Sood, A., Gurley, T., Quirk, L., Liu, Y., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.07.018 · Cited by 54
Self-citationAdvances in Locoregional and Systemic Treatments for Hepatocellular Carcinoma
Singal, A. G., Salem, R., Pinato, D. J., & Pillai, A. A. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.03.047 · Cited by 56
Self-citationMoeckli, B., Wassmer, C., Hajji, S. E., Kumar, R., Ribeiro, J. R., Tabrizian, P., Feng, H., Schnickel, G. T., Kulkarni, A. V., Allaire, M., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001289 · Cited by 51
Mahnoor, M., Malik, K., Kazmi, A., Sultana, T., Raja, N. I., Bibi, Y., Abbas, M., Badruddin, I. A., Ali, M. M., & Bashir, M. N. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e41654 · Cited by 51
“Although appropriate treatment might lessen the possibility of disease development, patients with cirrhosis and hepatocellular carcinoma may develop in those with persistently acceptable levels of alanine transaminase [149].”
RetractedPrecision surgery for hepatocellular carcinoma
Magyar, C. T. J., Rajendran, L., Li, Z., Banz, V. M., Vogel, A., O'Kane, G. M., Chan, A. C. Y., & Sapisochín, G. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00434-5 · Cited by 49
Jiang, H., Yang, C., Chen, Y., Wang, Y., Wu, Y., Chen, W., Ronot, M., Chernyak, V., Fowler, K. J., Bashir, M. R., et al. (2023) · Radiology · doi:10.1148/radiol.230527 · Cited by 48
Adjuvant and neoadjuvant therapies for hepatocellular carcinoma
Vogel, A., Grant, R. C., Meyer, T., Sapisochín, G., O'Kane, G. M., & Saborowski, A. L. (2023) · Hepatology · doi:10.1097/hep.0000000000000726 · Cited by 53
Vitale, A., Romano, P., Cillo, U., Writing Group for the HE.RC.O.LE.S Collaborative Group, Writing Group for the ITA.LI.CA Collaborative Group, Groups, H. R. O. L. S. A. I. L. C. C., Busti, M., Nezi, G., Carlis, R. D., Ratti, F., et al. (2024) · JAMA Surgery · doi:10.1001/jamasurg.2024.1184 · Cited by 47
RNA nanotherapeutics for hepatocellular carcinoma treatment
Yuan, Y., Sun, W., Xie, J., Zhang, Z., Luo, J., Han, X., Xiong, Y., Yang, Y., & Zhang, Y. (2024) · Theranostics · doi:10.7150/thno.102964 · Cited by 55
Li, Z., Liu, J., Zhang, B., Yue, J., Shi, X., Cui, K., Liu, Z., Chang, Z., Sun, Z., Li, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47420-3 · Cited by 48
“Adjuvant immune checkpoint inhibitor-based systemic therapy was recently recommended by the AASLD guideline for the treatment of HCC in patients at high risk of recurrence after liver resection 9 .”
Kumar, A., Acharya, S. K., Singh, S. P., Duseja, A. K., Madan, K., Shukla, A., Arora, A., Anand, A. C., Bahl, A., Soin, A. S., et al. (2023) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2023.08.005 · Cited by 43
Fiehn, F., Beisel, C., & Binder, M. (2024) · Current Opinion in Virology · doi:10.1016/j.coviro.2024.101423 · Cited by 47
Non-alcoholic fatty liver disease-related hepatocellular carcinoma
Daher, D., Dahan, K. S. E., & Singal, A. G. (2023) · Journal of Liver Cancer · doi:10.17998/jlc.2022.12.30 · Cited by 45
Self-citationChalasani, N., Gómez, E. V., Loomba, R. S., Yates, K. P., Diehl, A. M., Neuschwander‐Tetri, B. A., Dasarathy, S., Kowdley, K. V., Terrault, N. A., Wilson, L., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000896 · Cited by 42
“[20,22] Major adverse cardiovascular events (MACEs) included death from heart or cerebrovascular events or the occurrence of new and nonfatal cardiovascular and cerebro-vascular episodes (myocardial infarction, unstable angina, heart failure, and stroke).”
The current status and future of targeted-immune combination for hepatocellular carcinoma
Hao, L., Li, S., Ye, F., Wang, H., Zhong, Y., Zhang, X., Hu, X., & Huang, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1418965 · Cited by 49
Lanza, C., Ascenti, V., Amato, G. V., Pellegrino, G., Triggiani, S., Tintori, J., Intrieri, C., Angileri, S. A., Biondetti, P., Carriero, S., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020314 · Cited by 42
“B and Eastern Cooperative Oncology Group performance status (PS) of 0 [8–10].”
Lyshchik, A. P., Wessner, C. E., Bradigan, K., Eisenbrey, J. R., Forsberg, F., Yi, M., Keith, S. W., Kono, Y., Wilson, S. R., Medellin, A., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000558 · Cited by 39
Liu, X., Cai, Y., Zhang, Y., Zhang, H., Tian, S., Gong, Y., Song, Q., Chen, X., Ma, X., Wen, Y., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107526 · Cited by 39
Non-invasive tests for alcohol-associated liver disease
Israelsen, M. E., Rungratanawanich, W., Thiele, M. S., & Liangpunsakul, S. (2024) · Hepatology · doi:10.1097/hep.0000000000000885 · Cited by 37
“[122,123] Alpha-fetoprotein is a commonly used blood-based marker for HCC surveillance.”
Kao, S. Z., Sangha, K., Fujiwara, N., Hoshida, Y., Parikh, N. D., & Singal, A. G. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102755 · Cited by 38
Self-citationDawson, L. A., Ringash, J. G., Fairchild, A. M., Stos, P. M., Dennis, K. E. B., Mahmud, A., Stuckless, T., Vincent, F., Roberge, D., Follwell, M. J., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00438-8 · Cited by 37
Self-citationHepatocellular Carcinoma Surveillance Patterns and Outcomes in Patients With Cirrhosis
Daher, D., Dahan, K. S. E., Cano, A., Gonzales, M. A., Ransom, C., Jaurez, E., Carranza, O., Quirk, L., Morgan, T. M., Gopal, P., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.08.003 · Cited by 36
Self-citationLiu, C., Cheng, P., Fang, Y., Chen, C.-Y., Kao, W., Lin, C., Yang, S., Shih, Y., Peng, C., Chang, Y., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.09.038 · Cited by 36
Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma
Alden, S. L., Lim, M., Kao, C., Shu, D. H., Singal, A. G., Noonan, A. M., Griffith, P., Baretti, M., Ho, W. J., Kamel, I. R., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0072 · Cited by 35
Self-citationClinical management of intrahepatic cholangiocarcinoma: surgical approaches and systemic therapies
Ruff, S. M., & Pawlik, T. M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1321683 · Cited by 38
“According to National Comprehensive Cancer Network (NCCN) guidelines and European Association of the Study of Liver (EASL) guidelines, patients with a solitary lesion, anatomically resectable cancer, no severe comorbidities, and adequate future liver remnant (FLR) should be considered candidates for surgery (9, 10).”
BackgroundInfluentialYang, D.-L., Ye, L., Zeng, F.-J., Liu, J., Yao, H., Nong, J.-L., Liu, S., Peng, N., Li, W.-F., Wu, P., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001229 · Cited by 37
Dawit, H., Lam, E., McInnes, M. D. F., van der Pol, C. B., Bashir, M. R., Salameh, J., Levis, B., Sirlin, C. B., Chernyak, V., Choi, S. H., et al. (2024) · Radiology · doi:10.1148/radiol.231501 · Cited by 37
ESR Essentials: diagnosis of hepatocellular carcinoma—practice recommendations by ESGAR
Cannella, R., Zins, M., & Brancatelli, G. (2024) · European Radiology · doi:10.1007/s00330-024-10606-w · Cited by 34
Oh, J. H., & Sinn, D. H. (2024) · Journal of Liver Cancer · doi:10.17998/jlc.2024.02.27 · Cited by 34
“7,9 Similarly, the European Association for the Study of the Liver (EASL) recommends multidisciplinary discussions, especially in managing smaller lesions and in formulating surgical strategies.”
BackgroundKamaya, A., Fetzer, D. T., Seow, J. H.-S., Burrowes, D. P., Choi, H. H., Dawkins, A. A., Fung, C. I., Gabriel, H. A., Hong, C. W., Khurana, A., et al. (2024) · Radiology · doi:10.1148/radiol.240169 · Cited by 34
Current Treatment Methods in Hepatocellular Carcinoma
Krupa, K., Fudalej, M. M., Cencelewicz-Lesikow, A., Badowska-Kozakiewicz, A. M., Czerw, A. I., & Deptała, A. (2024) · Cancers · doi:10.3390/cancers16234059 · Cited by 37
“Child–Turcotte–Pugh A patients with good performance status have been included to assess the effectiveness of these treatments; however, well-selected patients with Child–Turcotte–Pugh B7 are capable of tolerating those therapies [10].”
Ivancovsky Wajcman, D., Byrne, C. J., Dillon, J. F., Brennan, P. N., Villota-Rivas, M., Younossi, Z. M., Allen, A. M., Crespo, J., Gerber, L. H., & Lazarus, J. V. (2026) · Hepatology · doi:10.1097/hep.0000000000001058 · Cited by 33
“On the contrary, hepatocellular carcinoma management guidelines align in recommending alcohol avoidance for all patients, [127,128] a recommendation that followed a statement by the American Society of Clinical Oncology [129] that alcohol use is related to hepatocellular carcinoma.”
MASLD-related HCC: Multicenter study comparing patients with and without cirrhosis
Vitellius, C., Desjonqueres, E., Lequoy, M., Amaddeo, G., Fouchard, I., Nkontchou, G., Canivet, C. M., Ziol, M., Regnault, H., Lannes, A., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101160 · Cited by 37
“Indeed, biannual screening for HCC is recommended for patients with cirrhosis 18,19 but not for those without it.”
Liu, M., & Wen, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e38444 · Cited by 36
“According to the 2023 guidelines set forth by the American Association for the Study of Liver Diseases (AASLD), the utilization of biomarkers, specifically AFP alone, for diagnosing early-stage HCC is discouraged due to its inadequate detection accuracy [14].”
MethodShin, H., & Yu, S. J. (2025) · Journal of Liver Cancer · doi:10.17998/jlc.2025.02.03 · Cited by 32
Hepatocellular Carcinoma Screening in a Contemporary Cohort of At-Risk Patients
Daher, D., Dahan, K. S. E., Rich, N. E., Tayob, N., Merrill, V., Huang, D. Q., Yang, J. D., Kulkarni, A. V., Kanwal, F., Marrero, J. A., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.8755 · Cited by 31
Self-citationBrahmania, M., Rogal, S. S., Serper, M., Patel, A., Goldberg, D. S., Mathur, A. K., Wilder, J. M., Vittorio, J., Yeoman, A. D., Rich, N. E., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000413 · Cited by 31
“[95] However, SDOH factors negatively influence access to HCC screening and surveillance protocols; therefore, patients from lower SES classes or public insurance have experienced significant rates of late-stage cancer diagnosis and delayed treatment, leading to inferior cancer outcomes.”
Metadata
- Authors
- Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., Mendiratta-Lala, M., Brown, D. B., Rilling, W. S., Goyal, L., Wei, A. C., & Taddei, T. H.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Johns Hopkins University (US)
- University of California, San Francisco (US)
- Mayo Clinic (US)
- University Health Network (CA)
- Oregon Health & Science University (US)
- Northwestern Medical Faculty Foundation (US)
- University of California, Los Angeles (US)
- University of Pennsylvania (US)
- Department of Radiology, University of Michigan Medical Center, Ann Arbor, Michigan, USA
- Vanderbilt University Medical Center (US)
- Medical College of Wisconsin (US)
- Stanford Medicine (US)
- Memorial Sloan Kettering Cancer Center (US)
- Yale University (US)
- Corresponding author
- Singal, Amit G.
- ORCID
- Venue
- Hepatology
- Published
- 2023-05-22
- Volume
- 78
- Issue
- 6
- Pages
- 1922-1965
- ISSN
- 0270-9139 (ISSN-L)
- PMC
- PMC10663390
- OpenAlex
- W4377011124
- Cited by
- 2,052
- References
- 341
- Citations by year
- 2026: 760 · 2025: 724 · 2024: 467 · 2023: 97
- FWCI
- 346.25
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- American Association for the Study of Liver Diseases
- Gilead Sciences
- Boston Scientific Corporation
- Exelixis
- Incyte
- Cancer Research UK (26813)
- Eisai
- Ipsen
- Sirtex Medical
- National Institutes of Health (UL1TR001863)
- Genentech
- National Cancer Institute (P50CA062924, R01CA285544)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Keywords
- hepatocellular carcinoma, hepatocellular carcinoma prevention, hepatocellular carcinoma diagnosis, hepatocellular carcinoma treatment, liver cancer, clinical guidelines
- MeSH terms
- Contrast Media, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Tomography, X-Ray Computed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
